E
Esperion Therapeutics, Inc. (ESPR)
NGM – Real Time Price. Currency in USD
3.17
+0.02 (0.63%)
At close: Jun 26, 2026, 4:00 PM EDT
3.16
-0.01 (-0.32%)
After-hours: Jun 26, 2026, 7:17 PM EDT
Get all premium features to the best stock analysis tool
Find any stock by ticker or company name
NGM – Real Time Price. Currency in USD
3.17
+0.02 (0.63%)
At close: Jun 26, 2026, 4:00 PM EDT
3.16
-0.01 (-0.32%)
After-hours: Jun 26, 2026, 7:17 PM EDT
No Data
There are no news for this stock.
Total debt $543.8M significantly exceeds cash reserves ($156.2M), raising financial stability concerns
Total current assets $459.5M exceed Total current liabilities $300.4M, highlighting excellent liquidity
Debt-to-equity ratio (-1.8) is well below the industry average (-0.8), showcasing prudent financial management
Interest coverage ratio (-0.3x) is dangerously low, suggesting debt repayment risks
Negative free cash flow -$27.9M limits the company's ability to reinvest or pay down debt
| NAME | RATIO | INDUSTRY | 5Y TREND | SCORE |
|---|---|---|---|---|
| Current ratio | 1.53 | 2.52 | 8.0 | |
| Quick ratio | 1.18 | 1.78 | 7.0 | |
| Debt to Equity | N/A | -0.80 | 1.0 | |
| Debt to Assets | 1.18 | 0.73 | 1.0 | |
| Interest coverage | -0.33 | -13.90 | 1.0 | |
| Weighted average score | 3.6 | |||
| METRIC | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|
| Total Revenue | 75M | 116M | 332M | 403M | 418M |
| Gross Profit | 48M | 73M | 264M | 274M | 286M |
| Operating Income | -180M | -156M | 54M | 60M | 76M |
| Net Income | -234M | -209M | -52M | -23M | -7M |
| EBITDA | -179M | -155M | 54M | 60M | 76M |
| NAME | REVENUE GROWTH | EPS GROWTH | SCORE |
|---|---|---|---|
| Current quarter | 12.25 | 92.86 | 8.5 |
| Next quarter | 13.05 | 100.89 | 9.0 |
| Current year | -3.85 | 63.64 | 5.5 |
| Next year | 15.79 | 779.17 | 9.5 |
| Weighted average score | 8.1 | ||
| NAME | REVENUE | NET INCOME | EPS | FCF | SCORE |
|---|---|---|---|---|---|
| Q/Q | -52.44 | -140.74 | -145.44 | -161.68 | 1.0 |
| Y/Y | 23.25 | 37.72 | 52.38 | 7.36 | 8.8 |
| 3y average | 87.04 | 47.3 | 63.08 | 50.06 | 10 |
| 5y average | 38.36 | 13.52 | 34.69 | -4.52 | 7.3 |
| Weighted average score | 6.8 | ||||
Insufficient positive free cash flow for DCF analysis
| NAME | CURRENT | INDUSTRY | SCORE |
|---|---|---|---|
| Dividend yield | 0.00 | N/A | 1.0 |
| Payout ratio | 0.00 | N/A | 1.0 |
| 5-year dividend growth rate | N/A | N/A | 1.0 |
| Years of dividend increase | N/A | N/A | 1.0 |
| Weighted average score | 1.0 | ||
Insufficient positive free cash flow for DCF analysis
| NAME | SCALE | SCORE |
|---|---|---|
| Market share | None | 1.0 |
| Intangible assets | None | 1.0 |
| Switching costs | None | 1.0 |
| Network effect | None | 1.0 |
| Economies of scale | None | 1.0 |
| Weighted average score | 1.0 | |